Difference between revisions of "Angiomyolipoma"
Jump to navigation
Jump to search
| Line 89: | Line 89: | ||
</ref> | </ref> | ||
**Melan A +ve in ~87% of cases (13/15). | **Melan A +ve in ~87% of cases (13/15). | ||
*Epithelial markers -ve | *Epithelial markers -ve<ref name=Ref_GUP324>{{Ref GUP|324}}</ref>, e.g. EMA and AE1/AE3. | ||
*SMA +ve. | *SMA +ve. | ||
*CD117 +ve/-ve. | *CD117 +ve/-ve. | ||
| Line 96: | Line 96: | ||
**Epithelioid variant of AML +ve. | **Epithelioid variant of AML +ve. | ||
**Conventional AML -ve. | **Conventional AML -ve. | ||
===Epithelioid AML versus Xp11.2 translocation carcinoma=== | |||
[[ISUP]] recommends:<ref name=pmid25025364/> | |||
*PAX8 -ve. | |||
**Positive in Xp11.2 translocation carcinoma. | |||
*CAIX -ve. | |||
*AE1/AE3 -ve. | |||
*EMA -ve. | |||
==See also== | ==See also== | ||